Evidence map›Paper›PMID 40164700›Full record

ArticleProstate cancer and prostatic diseases2025

Racial variation in the advanced prostate cancer genome.

Emily M Feng, Jenny Vo-Phamhi, Aishwarya N Subramanian, Mikhail Dias, Adam Foye, Jake Vinson, Julian C Hong, Stephen J Freedland, Joshi J Alumkal, Himisha Beltran and 9 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Emily M FengHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Jenny Vo-PhamhiHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Aishwarya N SubramanianHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Mikhail DiasHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Adam FoyeHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Jake VinsonProstate Cancer Clinical Trials Consortium (PCCTC), New York, NY, USA.ORCID 0009-0000-0405-7854
Julian C HongHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-5172-6889
Stephen J FreedlandDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-8104-6419
Joshi J AlumkalDepartment of Internal Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-1278-0166
Himisha BeltranDepartment of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-3259-2226
Colm MorrisseyDepartment of Urology, University of Washington School of Medicine, Seattle, WA, USA.
Peter S NelsonDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-5451-5726
Arul M ChinnaiyanDepartments of Pathology and Urology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-9282-3415
Rahul AggarwalHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-7003-7982
Eric J SmallHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-3191-6268
David A QuigleyHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-4726-1473
Martin SjöströmHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Shuang G ZhaoDepartment of Human Oncology, University of Wisconsin-Madison, Madison, WI, USA.
William S ChenHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. will.chen@ucsf.edu.

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
NCI NIH HHS P50 CA097186
6 · The paper itself

Abstract

backgroundRacial differences in metastatic castration-resistant prostate cancer (mCRPC) genomes have not yet been fully studied. We aimed to investigate transcriptomic, mutational, and clinical differences by race in a large multi-institutional cohort of men with mCRPC.

methodsGenomic and clinicopathologic data from four mCRPC tumor biopsy cohorts were obtained and aggregated. Gene set enrichment analyses were performed to assess pathway-level differences in gene expression by patient race. DNA alteration frequencies of known prostate cancer driver genes and clinical outcomes were compared across racial groups.

resultsIn our cohort of 445 men with mCRPC, tumors from African American patients (N = 26) demonstrated higher expression of MYC pathway genes (FDR q = 0.03) and lower expression of IFN-γ, IL-6/JAK/STAT3, and inflammatory pathway genes (FDR q < 0.001) compared to tumors from European American patients. TMPRSS2:ERG gene fusions were observed more frequently in tumors from European American compared to African American patients (41% vs. 11%, P = 0.015). Asian patients (N = 9) and other racial groups comprised a small minority of our cohort. No differences in overall survival were noted across racial groups.

conclusionsDespite demonstrating similar clinical outcomes, cancers from African Americans display distinct tumor biology. Specifically, we observed racial differences in expression of prostate cancer driver gene pathways (including potential clinically actionable pathways of IFN-γ and JAK/STAT) and DNA alterations, including TMPRSS2:ERG gene fusion. Our findings highlight the importance of racial diversity in future genomic profiling and clinical trials efforts.

Indexed as

Biomarkers, TumorProstatic Neoplasms, Castration-ResistantAgedAsianBlack or African AmericanGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMutationPrognosisTranscriptomeWhiteBiomarkers, Tumor

Identifiers

PMID40164700
PMCPMC12643939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.